Safety of ferucarbotran in MR imaging of the liver: A pre- and postexamination questionnaire-based multicenter investigation

Journal of Magnetic Resonance Imaging

Volumn 29, Issue 1, 2009, Pages 106-111

  Onishi, Hiromitsu ^a   Murakami, Takamichi ^b   Kim, Tonsok ^a   Hori, Masatoshi ^a   Hirohashi, Shinji ^c   Matsuki, Mitsuru ^d   Narumi, Yoshifumi ^e   Imai, Yasuharu ^f   Sakurai, Kousuke ^g   Nakamura, Hironobu ^a  

^a OSAKA UNIVERSITY   (Japan)

^b KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c NARA MEDICAL UNIVERSITY   (Japan)

^d OSAKA MEDICAL COLLEGE   (Japan)

^e OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^f Ikeda Municipal Hospital   (Japan)

^g Rinku General Medical Center   (Japan)

Author keywords

Adverse reaction; Ferucarbotran; Liver; Magnetic resonance imaging; Safety; Superparamagnetic iron oxide

Indexed keywords

FERUCARBOTRAN;

ABDOMINAL DISCOMFORT; ABDOMINAL DISTENSION; ABDOMINAL PAIN; AGED; ANOREXIA; ARTHRALGIA; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONSTIPATION; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DIZZINESS; DRUG SAFETY; DYSURIA; EDEMA; EPISTAXIS; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL DISEASE; HEADACHE; HEART PALPITATION; HEARTBURN; HEMATURIA; HEMORRHOID; HEPATOGRAPHY; HUMAN; INFORMED CONSENT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; NAIL DISEASE; NAUSEA; NEUROPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; ORTHOSTATIC HYPOTENSION; PHARYNX DISEASE; POLLAKISURIA; PRIORITY JOURNAL; PRURITUS; QUESTIONNAIRE; RASH; RIGOR; SIDE EFFECT; STOMATITIS; TASTE; THORAX PAIN; TOOTH PAIN;

AGED; DIZZINESS; HUMANS; IRON; JAPAN; LIVER; LIVER DISEASES; NAUSEA; OXIDES; QUESTIONNAIRES; RISK ASSESSMENT; VOMITING;

EID: 60349114206     PISSN: 10531807     EISSN: 15222586     Source Type: Journal    
DOI: 10.1002/jmri.21608     Document Type: Article

References (10)

1. Kehagias DT, Gouliamos AD, Smyrniotis V, Vlahos LJ. Diagnostic efficacy and safety of MRI of the liver with superparamagnetic iron oxide particles (SH U 555 A). J Magn Reson Imaging 2001;14:595-601.
2. Kopp AF, Laniado M, Dammann F, et al. MR imaging of the liver with Resovist: safety, efficacy, and pharmacodynamic properties. Radiology 1997;204:749-756.
3. Reimer P, Rummeny EJ, Daldrup HE, Balzer T, Tombach B, Berns T, Peters PE. Clinical results with Resovist: a phase 2 clinical trial. Radiology 1995;195:489-496.
4. Hamm B, Staks T, Taupitz M, et al. Contrast-enhanced MR imaging of liver and spleen: first experience in humans with a new super-paramagnetic iron oxide. J Magn Reson Imaging 1994;4:659-668.
5. Reimer P, Balzer T. Ferucarbotran (Resovist): a new clinically approved RES-specific contrast agent for contrast-enhanced MRI of the liver: properties, clinical development, and applications. Eur Radiol 2003;13:1266-1276.
6. Kirchin MA, Runge VM. Contrast agents for magnetic resonance imaging: safety update. Top Magn Reson Imaging 2003;14:426-435.
7. Bellin MF, Webb JA, Van Der Molen AJ, Thomsen HS, Morcos SK. Safety of MR liver specific contrast media. Eur Radiol 2005;15: 1607-1614.
8. Yasuda R, Munechika H. Delayed adverse reactions to nonionic monomeric contrast-enhanced media. Invest Radiol 1998;33:1-5.
9. Reynolds JEF, Parfitt K, Parsons AV, et al. Nutrition agents and vitamins. In: Martindale: The extra pharmacopoeia. 31st ed. London: Pharmaceutical Press, 1996. p 1349-1396.
10. Katayama H, Yamaguchi K, Kozuka T, et al. Adverse reactions to ionic and nonionic contrast media: a report from the Japanese committee on the safety of contrast media. Radiology 1990;175: 621-628.